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Mutations in MAP3K1 Cause 46,XY Disorders
of Sex Development and Implicate a Common Signal
Transduction Pathway in Human Testis Determination
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Investigations of humans with disorders of sex development (DSDs) resulted in the discovery of many of the now-known mammalian
sex-determining genes, including SRY, RSPO1, SOX9,NR5A1,WT1,NR0B1, andWNT4. Here, the locus for an autosomal sex-determining
gene was mapped via linkage analysis in two families with 46,XY DSD to the long arm of chromosome 5 with a combined, multipoint
parametric LOD score of 6.21. A splice-acceptor mutation (c.634-8T>A) inMAP3K1 segregated with the phenotype in the first family and
disrupted RNA splicing. Mutations were demonstrated in the second family (p.Gly616Arg) and in two of 11 sporadic cases (p.Leu189Pro,
p.Leu189Arg)—18% prevalence in this cohort of sporadic cases. In cultured primary lymphoblastoid cells from family 1 and the two
sporadic cases, these mutations altered the phosphorylation of the downstream targets, p38 and ERK1/2, and enhanced binding of
RHOA to the MAP3K1 complex. Map3k1 within the syntenic region was expressed in the embryonic mouse gonad prior to, and after,
sex determination. Thus, mutations in MAP3K1 that result in 46,XY DSD with partial or complete gonadal dysgenesis implicate this
pathway in normal human sex determination.Sex determination in mammals is genetically controlled,
with the expression of SRY (MIM480000) on the Y chromo-
some causing the undifferentiated gonad to develop as
a testis.1 In turn, hormones secreted by the testis cause the
Wolffianducts to differentiate as seminal vesicles, vas defer-
ens, and epididymis, and the Mu¨llerian ducts to regress. In
the absence of a Y chromosome and expression of SRY, the
undifferentiated gonad develops as an ovary, the Wolffian
ducts regress, and the Mu¨llerian ducts develop as Fallopian
tubes, uterus, and the upper third of the vagina. If the
process of gonadal development goes awry, disorders of
sex development (DSDs) may result (46,XX DSD [MIM
400045], 46,XY DSD [MIM 400044]).2 Previously, these
were known as intersex disorders or as either male and
female pseudohermaphroditismor truehermaphroditism.3
Among the genes that have been identified by studying
individuals with 46,XX DSD are SRY4 and RSPO1 (MIM
609595).5 Among those identified by studying individuals
with 46,XY DSD are SRY,6 SOX9 (MIM 608160),7 NR5A1
(MIM 184757),8 WT1 (MIM 607102),9,10 NR0B1 (MIM
300473),11 and WNT4 (MIM 603490).12 The phenotype
of the affected individual, manifested by the degree of
masculinization or feminization of the gonads and
internal and/or external genitalia, is often determined by
the specific genetic mutations and, presumably, modifier
genes. Individuals may be completely masculinized or
feminized or have ambiguous genitalia.1Human Genetics Program, New York University School of Medicine, New Y
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1970s.13–15 These studies anticipated sex-limited transmis-
sion of an autosomal-dominant or X-linked trait from
parents with the nonpenetrant genotype (46,XX) to those
with the penetrant genotype (46,XY), accounting for the
obvious lack of reproductive fitness. Most of these families
were lost to follow-up, but one was recruited in the 1990s
for future linkage and positional cloning studies and is re-
ported here.15 Another family, with 11 affected individ-
uals, was reported in 2003.16 Here, we describe mutations
in MAP3K1 (MIM 600982) (also known as MEKK1) that
are associated with both familial and sporadic cases of
46,XY DSD, including one in the index family. These
studies add MAP3K1 and the mitogen-activated protein
kinase (MAPK) signaling pathway to the repertoire of
genetic pathways that control normal human testis devel-
opment and identify mutations in this gene as a prevalent
cause of 46,XY DSD.
In 2003, we mapped a gene, which, when mutated, was
likely to be causative of the phenotype in family 1, to the
long arm of chromosome 5.17 This family was from France,
was of European descent, and included six women with
46,XY complete (IV-3 and IV-21 in Figure 1 and Table S1
[available online]) or partial (II-12, III-35, IV-2, and IV-27)
gonadal dysgenesis. One of the women with partial
gonadal dysgenesis (II-12) had clitoral hypertrophy and
hirsutism. Three of the women had gonadal tumorsork, NY 10016, USA; 2CHU Nantes, Service de Ge´ne´tique Medicale, 44093
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Figure 1. Pedigrees from Two Families of Interest Exhibiting Sex-Limited Autosomal-Dominant Mendelian Inheritance of 46,XY DSD
Shading indicates that the individual has 46,XY DSD or 46,XY complete gonadal dysgenesis. Circles indicate female sex of rearing, and
squares indicatemale sex of rearing. Asterisks (*) indicate individuals who were tested and found to have the c.IVS2-8T>Amutation. Plus
signs (þ) indicate individuals who were tested and found to have the p.Gly616Arg mutation. A strikethrough indicates a deceased indi-
vidual.(III-35, IV-2, and IV-3). Four men had genital abnormali-
ties, including one with first-degree hypospadias with
chordee (III-29) and three with perineal hypospadias
(II-10, III-13, and IV-28). One of these individuals had
micropenis and cryptorchidism (III-13). The man with
first-degree hypospadias and chordee had normal fertility
and fathered two children: one with perineal hypospadias
and chordee (IV-28) and the other with 46,XY partial
gonadal dysgenesis (IV-27). No extraurogenital abnormali-
ties were observed in any individuals. Family 2 was from
New Zealand and included five females with complete
gonadal dysgenesis (II-5, II-6, II-7, III-4, and IV-2). This
familywas of Northern European origin andhad amaximal
LOD score of 1.14 at D5S2068 (see Table S2 for LOD scores
and Table S3 for primer sequences). The combined LOD
score for both families was 4.62 at D5S398; the multipoint
LOD score was 6.21.
On the basis of linkage recombination breakpoints, the
critical region between D5S1969 and D5S2028 encom-
passed 5 Mb of DNA and 34 candidate genes. Only two
genes within this region, Map3k1 (Figure 2) and Mier3
(data not shown), demonstrated high levels of expression
within 13.5 days postcoitum (dpc) in mouse gonads, and
the expression was approximately equal in male and
female gonads, as previously reported.18 Map3k1 expres-
sion was also observed throughout the mouse embryonic
gonad at 11.5 dpc, the sex-determining stage of gonad
development (Figure 2B).19 Staining occurred within the
testis cords at 13.5 dpc in a pattern indicative of Sertoli
cell expression (Figure 2H).The AmericanSequence analysis of MIER3 (NM_152622.3) and
MAP3K1 (NM_005921.1) (Table S4) in affected individuals
in the French family 1 identified only one previously
unidentified heterozygous variant in the polypyrimidine
track of the splice-acceptor site in intron 2 of MAP3K1
(c.634-8T>A) that segregated with the phenotypes
(Figure 3A). This variant of MAP3K1 was not observed in
100 unrelated French individuals of European descent or
in the 1000 Genomes Project. Given the proximity of
this variant to the intron-exon boundary, a quantitative
PCR assay was developed to test the efficiency or fidelity
of mRNA splicing at this exon (Table S5). The level of
expression for the normal and affected samples was not
significantly different (Figure S1). However, variant cDNAs
resulting in heteroduplex molecules were identified in
samples from affected individuals by a second peak in
the SYBR-green-based qPCR dissociation curves
(Figure 3B). The splice products were analyzed by cloning
and sequencing. The cloned cDNAs from the affected
samples demonstrated both wild-type and aberrant
splicing that resulted in the addition of six nucleotides
into the RNA (c.633_634insAATCAG) and two amino
acid residues (p.Val211_Val212insIleGln) into the protein
in-frame at this site (Figure 3C). The ratio of the mutant
to wild-type transcript was > 1 in the lymphophoblastoid
cells of individuals carrying the mutation (Figure S1).
MAP3K1 was then sequenced in family 2 and in 11
sporadic cases. Mutations were identified in family 2
(c.1846G>A [p.Gly616Arg]) and in two unrelated sporadic
cases of 46,XY complete gonadal dysgenesis (c.566T>CJournal of Human Genetics 87, 898–904, December 10, 2010 899
Figure 2. Whole-Mount In Situ Hybridization of Wild-Type
Embryonic Gonads Reveals Strong Expression of Map3k1 at the
Sex-Determining Stage of Mouse Gonad Development
(A and B) Whole-mount staining of 13.5 dpc ovary (A) and testis
(B). Expression is detected in the mesonephric tubules, Wolffian
duct, and Mu¨llerian duct of both sexes and in the testis cords in
males.
(C) Negative control with sense RNA probe used.
(D) Longitudinal section through 13.5 dpc testis after Map3k1
whole-mount in situ hybridization (WMISH). The staining is de-
tected throughout the testis cords, and the smooth edge of this
profile (arrowheads in inset showing high magnification image
of cord in hatched box) indicates expression in Sertoli cells that
abut the basement membrane.
(E and F) Whole-mount expression analysis of 11.5 dpc female (E)
and male (F) gonads. The staining is prominent throughout the
900 The American Journal of Human Genetics 87, 898–904, Decemb[p.Leu189Pro] and c.566T>G [p.Leu189Arg]) (Figure 3A).
None of these variants was reported previously as a known
SNP, nor were they observed in 100 unrelated, ethnically
matched individuals tested specifically in our investigation
or in the 1000Genomes Project. Nomutationwas observed
in nine other sporadic cases of 46,XY complete gonadal
dysgenesis, suggesting a mutation prevalence of 18% in
this cohort. The p.Leu189Pro and p.Leu189Arg mutations
were reported by PolyPhen and SIFT20 to be likely to inter-
fere with function, whereas the heritable p.Gly616Arg
mutation was not. Nonetheless, this mutation resulted in
the substitution of a basic for a conserved neutral amino
acid at this site. The p.Leu189Arg mutation was observed
in the patient’s mother, whereas the p.Leu189Promutation
was not. The father of the patient with the p.Leu189Pro
mutation was not available for analysis.
We thendeterminedwhether themutations identified re-
sulted in altered MAP3K1 function. Previously, it has been
shownthatMAP3K1affects theMAPkinase cascadeby regu-
lating phosphorylation of the downstream targets p38
(MIM 600289), ERK1/2 (MIM 601795/MIM 176948), and
JNK (MIM 605431).21 The effects of three of the four
MAP3K1 mutations on phosphorylation of downstream
targetswere examinedbyquantitative immunoblot analysis
after serum starvation for 24 hr and subsequent serum
refeeding for an additional 1 hr in lymphoblastoid cells.
(A cell linewasnot available for thep.Gly616Argmutation.)
Under these culture conditions, the phosphorylation of p38
in two out of three mutant cell lines was greater than wild-
type, whereas levels of phospho-p38 in p.Leu189Pro were
not altered (Figures 4A and 4B, Table S6—these increases
were observed whether normalization was performed to
histone or to total p38). Levels of phospho-ERK were
increased in all the mutant cell lines in comparison to
wild-type (Figures 4A and 4B, Table S6). Thus, we conclude
that regulation of theMAPK signaling pathway is disrupted
by theMAP3K1mutations reported here, causing increased
activation in cultured lymphoblastoid cell lines.
To identify how these MAP3K1 mutations might cause
46,XY DSD, we began by identifying their positions
relative to the known protein-binding domains of
MAP3K1. The intron splice-acceptor mutation in family 1
inserts two amino acids in the middle of a domain
complementary to the interactive site of growth factor
receptor-bound protein 2 (GRB2 [MIM 108355]),22 and the
point mutations at codon 189 occurred within thegonads of both sexes and is detected in the mesonephric tubules
and associated Wolffian duct.
(G) Negative control with sense RNA probe used.
(H) Section of gonad shown in (B) (at level indicated by dashed
line). Staining is detected throughout the gonad (g), in contrast
to negligible staining in the adjacent mesonephric mesenchyme
(m), but the signal is highest in the coelomic epithelium and sub-
epithelial mesenchyme.
The dashed line in (G) indicates the boundary between gonad and
mesonephros. Abbreviations are as follows: WD, Wolffian duct;
MD, Mu¨llerian duct; MT, mesonephric tubules; CE, coelomic
epithelium; t, testis; m, mesonephros.
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Figure 3. Mutations in MAP3K1 in Patients with 46,XY DSD
(A) Schematic of MAP3K1 structure and mutation locations. Sequencing chromatograms of four mutations identified an amino acid
conservation taken from the UCSC Genome Browser. Alignment 1: invariant conservation of amino acids in ten species in the region
of exon 2 where sporadic mutation 1 and sporadic mutation 2 lie. Alignment 2: the mutation in family 2 lies in a less highly conserved
region.
(B) SYBR-green quantitative PCR dissociation curves. Control samples exhibited one form of cDNAwith a single dissociation curve peak,
whereas samples from family 1 exhibited heteroduplex and homoduplex cDNAs with two dissociation curve peaks indicating the pres-
ence of the mutant and wild-type forms.
(C) Chromatogram of MAP3K1 cDNA demonstrating insertion of six nucleotides in-frame into the mutant mRNA
(NM_005921.1:c.633_634insAATCAG) and two amino acid residues (p.Val211_Val212insIleGln) into the mutant protein.phylogenetically conserved 27 amino acid region that
comprises the focal adhesion kinase (FAK) binding site
(MIM 600758).23 Most significantly, all of these mutations
and the codon 616 mutation occurred in the amino third
of MAP3K1, a region that has been shown to interact with
RHOA(MIM165390).24 That study showed thatRHOAposi-
tively regulates MAP3K1 kinase activity by binding to its
N-terminal third, in the region in which the mutations
reported here have been identified.24 To test whether
MAP3K1 mutations affected the binding of endogenous
RHOA, we performed coimmunoprecipitation by immuno-
precipitating mutant (c.634-8T>A) and wild-type
complexeswith anti-MAP3K1andprobing the immunoblot
with anti-RHOA (Figure 4C). This experiment demonstrated
that thismutation resulted in enhancedbindingofRHOA inThe Americanthe mutant cell lines compared to wild-type. This increased
binding could not be accounted for on the basis of unequal
loading of MAP3K1-bearing complexes or on the basis of
enhanced expression of RHOA in the mutant cell lines—as
judged by immunoblot analysis (Figure 2S). In support of
this finding, the converse immunoprecipitation experi-
ments, with anti-RHOA, resulted in 2.1- to 2.8-fold increase
in binding of MAP3K1 in three mutant cell lines compared
to wild-type (p.Leu189Arg: p ¼ 0.0014; p.Leu189Pro: p ¼
4 3 1010; p.Val211_Val212insIleGln: p ¼ 0.0068) (Figures
4D and 4E). Thus, enhanced binding of RHOA to MAP3K1
might account for the increased activation of MAPK
signaling described earlier. The procedures were in accor-
dancewith the ethical standards of theNewYorkUniversity
Langone Medical Center institutional review board (studyJournal of Human Genetics 87, 898–904, December 10, 2010 901
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Figure 4. Effects of MAP3K1 Mutations on Phosphorylation of Downstream Targets and Binding of RHOA
(A) Dysregulation of MAPK signaling activity by MAP3K1mutations. Immunoblot analysis of cell lysates from human lymphoblastoid
cell lines cultured in suspension in RPMI medium without serum supplemented with 1% penicillin and streptomycin for 24 hr, then
refed serum for 1 hr. The blots were dual-hybridized overnight at 4C with primary antibodies against phosphorylated and total p38
and ERK1/2 (both at 1:2000) and detected with the use of infrared dye-conjugated secondary antibodies (1:5000). The cell lines are desig-
nated as ‘‘WT’’ for wild-type or by the specific mutation and affected individual in family 1. Infrared absorbance detects phosphorylated
signal at 680 nm (red) and total target activities at 800 nm (green). The histone H3 loading controls are also shown.
(B) Phosphorylated (phospho) p38 and ERK intensities normalized to histone H3 loading control intensity. The normalized intensities
are indicated on the y axis, and the cell lines are indicated on the x axis. A box and whisker plot of p.Leu189Arg and p.Leu189Pro was
represented by five measurements, whereas the p.Val211_Val212insIleGln and WT plots were represented by 15 and 25 measurements,
respectively. The bottom and top whisker hash lines indicate the minimum and maximum values, the box length represents the inter-
quartile range, and the dark horizontal line indicates themedian of the data. The p values were determined by comparing themutants to
WT controls for each set of mutations with the use of the Student’s t-test. Comparison of all mutant lines to all WT lines is denoted.
(C) Increased binding of RHOA to mutant MAP3K1. Proteins were immunoprecipitated with MAP3K1 antibody from lysates collected
from mutant (p.Val211_Val212insIleGln) and wild-type cell lines and were probed on immunoblots with the RHOA . Upper panel:
Mutant (p.Val211_Val212insIleGln) and wild-type cells were seeded in triplicates of 3 million cells. Triplicates were pooled and immu-
noprecipitated for each cell line. RHOA binding to MAP3K1 complexes in the wild-type (lane 1) was enhanced by the presence of the
p.Val211_Val212insIleGln mutation in MAP3K1 (lane 2). Lower panel: Equal loading of MAP3K1 complexes in each lane.
(D) Increased binding ofmutantMAP3K1 to RHOAdetected by immunoprecipitation.Mutant (p.Val211_Val212insIleGln, p.Leu189Pro,
and p.Leu189Arg) and two wild-type cell line lysates were pooled from three independent experiments, totaling ~9 million cells per
experiment, and pulled down (immunoprecipitated) with the use of anti-RHOA, then probed forMAP3K1 on immunoblots and normal-
ized to the histone bands. Upper panel: MAP3K1 binding was enhanced by the presence of the p.Val211_Val212insIleGln, p.Leu189Arg,
and p.Leu189Pro mutations in MAP3K1. Lower panel: Histone loading control of RHOA complexes in each lane.
(E) MAP3K1 intensities normalized to loading control intensity. The normalized intensities are indicated on the y axis, and the five cell
lines are indicated on the x axis. A box and whisker plot of p.Leu189Arg and p.Leu189Pro was represented by five measurements,
whereas the p.Val211_Val212insIleGln and WT plots were represented by 15 and 25 measurements, respectively. The p values were
determined by comparing the mutants to WT controls for each mutation set with the use of the Student’s t-test. Comparison of all
mutant lines to all WT lines is denoted.
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no. 10417), and proper informed consent was obtained. All
mice were bred under standard conditions of care and used
under licensed approval from the UK Home Office (PPL
30/2381).
An earlier study used linkage analysis and positional
cloning in a family with 46,XX DSD and palmoplantar
keratosis to identify RSPO1 as the mutated, disease-associ-
ated gene.5 The current study employed a similar approach
to identify mutations in MAP3K1 in families with 46,XY
DSD and subsequently in sporadic cases with this pheno-
type. These in-frame mutations provide a basis for the
autosomal-dominant, sex-limited inheritance. The pheno-
typic variation among affected members of family 1 might
be explained by the individual differences in aberrant
splicing in the developing gonad and, potentially, modifier
loci. In mice with a spontaneously occurring loss-of-func-
tion, 8 exon deletion of Map3k1 on a BALB/cGa back-
ground, the only reported phenotype was open eyelids at
birth.25 No genital abnormalities, skewing of the sex ratio,
or infertility were reported in that study. However, unlike
C57BL/6J, BALB/cGa is not a background known for its
sensitivity to disruptions in testis development.
One other gene in theMAP kinase pathway has an estab-
lished role in sex determination. Recently, some of us (A.G.,
N.W., and H.O.) identified the recessive boygirl (byg) muta-
tion, which, when homozygous on the C57BL/6J back-
ground, resulted in embryoswithXYgonadal sex reversal.26
The bygmutation, anA-to-T transversion inMap3k4 leading
to apremature stop codon, caused a growthdeficit in 11dpc
XY byg/byg gonads and a failure to supportmesonephric cell
migration, both early cellular processes normally associated
with testis development.On somegenetic backgrounds,XY
mice merely heterozygous for a loss-of-function allele of
Map3k4 developed as viable females. Homozygous mutant
11.5 dpc XY gonads demonstrated a dramatic reduction in
Sox9 and Sry at the transcript and protein levels, accounting
for the defect in Sertoli cell differentiation.
Here, we describe an unexpected activation of MAPK
targets in human lymphoblastoid cells from the sex-
reversing MAP3K1 mutations. Given that loss of
MAP3K4, and therefore a presumed deficit in MAPK
signaling, causes XY sex reversal in mice, an apparent
tension arises between observations in the two species.
How might this be resolved? Members of the MAP kinase
gene family could mediate the balance between the male
and female sex-determining pathways by affecting the
activities of the testis-promoting SOX9 and FGF9 (MIM
600921) and ovarian-promoting WNT4 and CTNNB1
(b-catenin) (MIM 116806) (reviewed in 27). It is worth
noting that such explanations do not require sexually
dimorphic expression of MAPK signaling components
during gonadogenesis because transcription of SOX9,
FGF9, andWNT4 is already sexually dimorphic. Previously,
it has been shown that the transcriptional activity of SOX9
in chondrocytes is regulated by the MAP3K1 binding
partner, RHOA,28–30 and that the increase in SOX9 levels
in chondrocytes induced by FGF2 (MIM 134920) is medi-The Americanated via the MAP kinase pathway.31 Axin (MIM 603816),
a member of the MAPK complex and an inhibitor of the
WNTsignaling pathway, interacts with b-catenin to reduce
its quantity.32,33 Stabilization of b-catenin in the XY gonad
causes male-to-female sex reversal, in part by reducing
SOX9 expression.34 Thus, the 46,XY DSD that is associated
with mutations in MAP3K1 may be caused by decreased
SOX9 activity, increased b-catenin activity, or both. Sorting
through these possibilities and others will require further
investigation, as will determining whether the functional
consequences of specific MAP3K1 mutations in lympho-
blastoid cell lines are similar to those in the embryonic
gonad. Indeed, disruption to (loss of) one part of the
MAPK signaling network is consistent with consequential
activation of other components elsewhere.
In summary, we have identified mutations in MAP3K1
that cause downstream alterations in the MAP kinase
signaling pathway in two familial and two sporadic cases
of 46,XY DSD. Mutations in this gene, as well as in SRY,
NR5A1, and DHH (MIM 605423), should be routinely
tested in individuals with 46,XY DSD.2Supplemental Data
Supplemental Data include two figures and six tables and can be
found with this article online at http://www.cell.com/AJHG/.Acknowledgments
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